New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn (NOSODIAG)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by University Hospital, Strasbourg, France.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00701948
First received: June 17, 2008
Last updated: April 27, 2010
Last verified: April 2010
  Purpose

This study aims to evaluate new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection. We made the hypothesis that these new dosages or new inflammatory markers could be more useful than dosage of inflammatory markers already used in clinical practice (especially the use of a combination of interleukins (6 or 8) and C-reactive protein for the management of newborns with a clinical suspicion of nosocomial bacterial infection and especially could allow to avoid excessive treatment with antibiotics


Condition
Nosocomial Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Interest of New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Evaluation of new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection. [ Time Frame: 48 hours and at 72 hours ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum


Estimated Enrollment: 240
Study Start Date: July 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
A-1
Proven nosocomial bacterial infection (NBI)
A-2
Possible NBI
B-1
Absence of NBI
B-2
Probable absence of NBI

  Eligibility

Ages Eligible for Study:   up to 90 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Newborn hospitalized in neonatal intensive care unit with a clinical suspicion of nosocomial bacterial infection

Criteria

Inclusion Criteria:

  • Newborns > 72 hours of life hospitalized in neonatal intensive or intermediate care unit presenting a clinical suspicion of NBI

Exclusion Criteria:

  • Early post-operative period ( surgery of less than 48 hours)
  • Multiple malformations
  • Newborn already included in the study for a previous septic events
  • Newborn treated with antibiotics in the last 24 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00701948

Contacts
Contact: Pierre Kuhn, MD 33 3 88 12 77 86 Pierre.kuhn@chru-strasbourg.fr

Locations
France
Service de Pédiatrie 2 - Hôpital d'Enfants CHU de Dijon; 10 - bld Maréchal de Lattre de Tassigny Recruiting
Dijon, France, 21079
Contact: Marc Labenne, MD    33 3 80 29 33 57    marc.labenne@chu-dijon.fr   
Principal Investigator: Marc Labenne, MD         
Sub-Investigator: Jean Bernard Gouyon, MD         
Sub-Investigator: Cyril Ferdinus, PhD         
Sub-Investigator: Gérard Lizard, PhD         
Service de Pédiatrie 2 - Hôpital de Hautepierre; 1 - Avenue Molière Recruiting
Strasbourg, France, 67 092
Contact: Pierre Kuhn, MD    33 3 88 12 77 86    Pierre.kuhn@chru-strasbourg.fr   
Principal Investigator: Pierre Kuhn, MD         
Sub-Investigator: Dominique Astruc, MD         
Sub-Investigator: Benoît Escande         
Sub-Investigator: Thomas Lavaux, PhD         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Pierre Kuhn, MD University Hospital, Strasbourg, France
  More Information

No publications provided

Responsible Party: Emmanuel LAVOUE, directeur Adjoint, Organization: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00701948     History of Changes
Other Study ID Numbers: 4108
Study First Received: June 17, 2008
Last Updated: April 27, 2010
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:
Late onset neonatal sepsis
Nosocomial bacterial infection
Inflammatory markers
multiplex dosage

Additional relevant MeSH terms:
Bacterial Infections
Cross Infection
Infection

ClinicalTrials.gov processed this record on July 20, 2014